News
NSPRZ
0.0090
+28.57%
0.0020
BUZZ-Silk Road tumbles, InspireMD rises after Medicare coverage proposal for stents
Reuters · 07/12/2023 14:48
BRIEF-InspireMD Inc Files For Stock Offering Of Up To 77.5 Million Shares Of Common Stock By Selling Stockholders - SEC Filing
Reuters · 05/23/2023 21:50
BRIEF-InspireMD Reports First Quarter 2023 Financial Results And Provides Business Update
Reuters · 05/16/2023 11:04
BRIEF-InspireMD Announces Successful First-In-Human Procedure Utilizing CGuard Prime, Its Next Generation Carotid Artery Stent Platform
Reuters · 05/01/2023 12:18
BRIEF-InspireMD To Report Q1 Financial Results On May 9
Reuters · 04/27/2023 13:25
More
Webull provides a variety of real-time NSPRZ stock news. You can receive the latest news about Inspiremd through multiple platforms. This information may help you make smarter investment decisions.
About NSPRZ
InspireMD, Inc. is a medical device company. The Company is focusing on the development and commercialization of its MicroNet stent platform technology for the treatment of vascular and coronary disease. Its MicroNet, a micron mesh sleeve, is wrapped over a stent to provide embolic protection in stenting procedures. Its CGuard carotid embolic prevention system (CGuard EPS) combines its MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. Its MGuard Prime Embolic Protection System (MGuard Prime EPS) is marketed for use in patients with acute coronary syndromes, notably acute myocardial infarction (heart attack) and saphenous vein graft coronary interventions (bypass surgery). It markets and sells MGuard Prime EPS, a bare-metal cobalt-chromium based stent, for the treatment of coronary disease in the European Union. It is also developing a neurovascular flow diverter (NGuard), which is an endovascular device.